

## Data Sharing Statement

<b>Article Info</b>	https://dx.doi.org/10.21037/jtd-23-1114	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	This study can share serum S100A12, PCT, CRP, neutrophil to lymphocyte ratio (NLR), and SAA measurement data on the first day of admission, the third day of anti-infection, and the seventh day of antiinfection. The correlation between S100A12 and different levels of MEWS scores (this has been rarely provided in previous studies).
4	Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the new technique or S100A12 detection value may be updated over time.
7	To whom will you share the data?	Respiratory and ICU physicians interested in studying S100A12 family or novel infection markers
8	For what type of analysis or purpose?	To investigate the application value of serum calcium binding protein S100A12 and modified early warning score (MEWS) in adult community-acquired pneumonia (CAP).
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: Email: 1113642201@qq.com.
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.